NCT00002109 is a Phase 3 clinical trial of Thymopentin in HIV Infections, sponsored by Immunobiology Research Institute.

Who is sponsoring NCT00002109?

NCT00002109 is sponsored by Immunobiology Research Institute.

What drugs are being tested in NCT00002109?

Interventions in NCT00002109: Thymopentin, Stavudine, Zidovudine, Zalcitabine, Didanosine.

What condition does NCT00002109 study?

NCT00002109 studies HIV Infections.

Is NCT00002109 still recruiting?

NCT00002109 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00002109

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy

Completed Phase 3 Last updated 23 June 2005

What this trial tests

Phase 3 trial testing Thymopentin in HIV Infections. Completed.

Quick facts

Lead sponsor	Immunobiology Research Institute
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Masking	double
Primary purpose	treatment
Sites	50 locations across United States, Puerto Rico

Drugs / interventions tested

Thymopentin (THYMOPENTIN) — full drug profile →
Stavudine — full drug profile →
Zidovudine (ZIDOVUDINE) — full drug profile →
Zalcitabine — full drug profile →
Didanosine (DIDANOSINE) — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Immunobiology Research Institute

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To confirm results from a previous study in which the combination of thymopentin plus zidovudine ( AZT ), an antiretroviral agent, slowed disease progression in HIV-infected asymptomatic patients. To evaluate the efficacy and safety of thymopentin in HIV-infected asymptomatic patients receiving either monotherapy with AZT, didanosine ( ddI ), or stavudine ( d4T ), or combination antiretroviral therapy with AZT / ddI or AZT / zalcitabine ( ddC ).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00002109 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immunobiology Research Institute
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00002109.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing